E
DGX icon

Ergoteles’s Quest Diagnostics DGX Stock Holding History

Ergoteles’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-19,033
Closed -$2.68M – 255
2023
Q2 		$2.68M Buy
+19,033
New +$2.62M 0.13% 204
2023
Q1 		– Sell
-27,075
Closed -$4.24M – 1368
2022
Q4 		$4.24M Buy
27,075
+24,928
+1,161% +$3.58M 0.16% 135
2022
Q3 		$263K Sell
2,147
-15,460
-88% -$2.04M 0.01% 1044
2022
Q2 		$2.34M Buy
17,607
+4,074
+30% +$555K 0.07% 280
2022
Q1 		$1.85M Buy
13,533
+8,575
+173% +$1.2M 0.07% 275
2021
Q4 		$858K Sell
4,958
-77,854
-94% -$11.8M 0.03% 462
2021
Q3 		$12M Buy
82,812
+79,154
+2,164% +$11.6M 0.44% 51
2021
Q2 		$483K Sell
3,658
-14,424
-80% -$1.89M 0.01% 822
2021
Q1 		$2.32M Buy
18,082
+10,882
+151% +$1.34M 0.07% 262
2020
Q4 		$858K Buy
+7,200
New +$878K 0.03% 358

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ergoteles's DGX Position: Q3 2023 in Review

Ergoteles sold out of Quest Diagnostics (DGX) in Q3 2023, closing a stake of 19,033 shares — an estimated $2.68M sold.

Ergoteles first reported a position in DGX in Q4 2020 and held it in 10 quarters. The position peaked at $12M in Q3 2021. 794 funds tracked by Wall St. Rank hold DGX as of Q3 2023.

  • Ergoteles reported no remaining Quest Diagnostics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 19,033 Quest Diagnostics shares in Q3 2023, an estimated $2.68M.
  • Ergoteles first reported a position in Quest Diagnostics in Q4 2020 and held it in 10 quarters.
  • Ergoteles's Quest Diagnostics position peaked at $12M in Q3 2021.
  • 794 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.